Rhythm Pharmaceuticals (RYTM) Net Cash Flow (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Net Cash Flow data on file, last reported at $7.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $7.5 million, down 55.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.4 million (down 184.33% YoY), and the FY2025 annual result was -$34.9 million, down 219.44% from the prior year.
• Net Cash Flow improved to $7.5 million in Q1 2026 per RYTM's latest filing, from $2.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $108.5 million in Q2 2024 and troughed at -$113.5 million in Q3 2024.
• A 5-year average of $162764.7 and a median of $6.1 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow plunged 193.85% in 2023, then jumped 1668.92% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$57.4 million in 2022, then surged by 92.48% to -$4.3 million in 2023, then surged by 1040.74% to $40.6 million in 2024, then tumbled by 95.05% to $2.0 million in 2025, then surged by 271.49% to $7.5 million in 2026.
• Business Quant data shows RYTM's Net Cash Flow at $7.5 million in Q1 2026, $2.0 million in Q4 2025, and -$83.7 million in Q3 2025.